A study of ADXS-DUAL and Nivolumab for the treatment of metastatic cervical cancer in women
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
Price : $35 *
At a glance
- Drugs ADXS Dual (Primary) ; Nivolumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- 11 Sep 2017 According to an Advaxis media release, this trial will be initiated in 1H 2018.
- 13 Jun 2017 According to an Advaxis media release, this study has been previewed at annual Investor & Analyst Day.
- 02 Jun 2017 New trial record